A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.

Nathalie ReixCharlotte MalinaMarie-Pierre ChenardJean-Pierre BellocqStéphanie DelpousSébastien MolièreAnthony SevrinKarl NeubergerCatherine TomasettoCarole Mathelin

Published in: Breast cancer research and treatment (2016)

HER2/ECD is a prognosis factor that is valuable in evaluating the neoadjuvant treatment efficiency. HER2/ECD also appears to be a helpful surveillance biomarker for the early diagnosis of relapses and to predict the fate of metastases. This study brings evidences to support the use of HER2/ECD in the management of HER2-positive breast cancer.

Keyphrases

positive breast cancer
rectal cancer
public health
lymph node
cell proliferation
locally advanced
transcription factor
squamous cell carcinoma
young adults
combination therapy